Antidrug antibodies in psoriasis: a systematic review (Q38151757)

29 August 2017

Antidrug antibodies in psoriasis: a systematic review (English)

1 reference

29 August 2017

1 reference

1 reference

L Hsu

1

1 reference

29 August 2017

B T Snodgrass

series ordinal

2

1 reference

29 August 2017

A W Armstrong

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

British Journal of Dermatology

29 August 2017

1 reference

29 August 2017

170

1 reference

29 August 2017

2

1 reference

29 August 2017

261-273

1 reference

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

29 August 2017

1 reference

Coronary artery disease in patients with psoriasis referred for coronary angiography

21 January 2018

1 reference

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

21 January 2018

1 reference

Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha

21 January 2018

1 reference

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

21 January 2018

1 reference

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

21 January 2018

1 reference

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy

21 January 2018

1 reference

Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring

21 January 2018

1 reference

Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.

21 January 2018

1 reference

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

21 January 2018

1 reference

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

21 January 2018

1 reference

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.

21 January 2018

1 reference

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

21 January 2018

1 reference

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

21 January 2018

1 reference

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

21 January 2018

1 reference

Dealing with immunogenicity of biologicals: assessment and clinical relevance

21 January 2018

1 reference

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

21 January 2018

1 reference

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.

21 January 2018

1 reference

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

21 January 2018

1 reference

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis

21 January 2018

1 reference

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJD.12654

1 reference

29 August 2017

1 reference